All In Biotech

Drug Trial Radar · NCT05489887

Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

A Phase II Study of Naxitamab Added to Induction Therapy for Subjects With Newly Diagnosed High-Risk Neuroblastoma

Last checked: Nov 20, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

93

Planned (sponsor's estimate)

Start

Sep 14, 2022

Primary completion

Sep 2029

Study completion Sep 2036

Sponsor

Lead sponsor
Giselle ShollerAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Y-mAbs Therapeutics
First posted
Aug 5, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 months, up to 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, multicenter clinical trial in subjects with newly diagnosed high-risk neuroblastoma to evaluate the efficacy and safety of administering naxitamab with standard induction therapy. The initial chemotherapy will include 5 cycles of multi-agent chemotherapy. Naxitamab will be added to all 5 Induction cycles. We hypothesize that the addition of anti-GD2 therapy to induction chemotherapy will result in improved end of induction responses and improved survival.

Conditions

  • Neuroblastoma

Interventions

  • NaxitamabDrug

    Naxitamab is a humanized (IgG1) anti-GD2 (hu3F8) monoclonal antibody for the treatment of neuroblastoma, osteosarcoma and other GD2-positive cancers. Naxitamab was granted accelerated approval by the FDA in 2020 as treatment (in combination with granulocyte-macrophage colony-stimulating factor - GM-CSF) for pediatric patients at least one year of age and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow demonstrating a partial response, minor response, or stable disease to prior therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Complete Response (CR) rate per 1993 INRC guidelinesTime frame: 6 to 12 months

Locations

26 sites in 4 countries. Site status is shown where the registry gives one.

  • University of Alabama/Children's of Alabama

    Birmingham, Alabama · Recruiting

  • Arkansas Children's Hospital

    Little Rock, Arkansas · Recruiting

  • UCSF Benioff Children's Hospital Oakland

    Oakland, California · Recruiting

  • Rady Children's Hospital

    San Diego, California · Recruiting

  • Connecticut Children's Hospital

    Hartford, Connecticut · Recruiting

  • University of Florida

    Gainesville, Florida · Recruiting

  • Nicklaus Children's Hospital

    Miami, Florida · Recruiting

  • Arnold Palmer Hospital for Children

    Orlando, Florida · Recruiting

  • Augusta University Health

    Augusta, Georgia · Recruiting

  • Kapiolani Medical Center for Women and Children

    Honolulu, Hawaii · Recruiting

  • Norton Children's Research Institute/Affiliated with University of Louisville School of Medicine

    Louisville, Kentucky · Recruiting

  • Children's Hospital and Clinics of Minnesota

    Minneapolis, Minnesota · Recruiting

  • Cardinal Glennon Children's Hospital

    St Louis, Missouri · Recruiting

  • Levine Children's Hospital

    Charlotte, North Carolina · Recruiting

  • Duke University

    Durham, North Carolina · Recruiting

  • Wake Forest University Health Sciences

    Winston-Salem, North Carolina · Withdrawn

  • Randall Children's Hospital

    Portland, Oregon · Recruiting

  • Penn State Milton S. Hershey Medical Center and Children's Hospital

    Hershey, Pennsylvania · Recruiting

  • Medical University of South Carolina

    Charleston, South Carolina · Recruiting

  • Dell Children's Blood and Cancer Center

    Austin, Texas · Recruiting

  • Virginia Commonwealth University

    Richmond, Virginia · Recruiting

  • GRAACC Hospital

    São Paulo, São Paulo, Brazil · Recruiting

  • UHC Sainte-Justine

    Montreal, Quebec, Canada · Recruiting

  • CHUQ

    Québec, Quebec, Canada · Recruiting

  • CIUSSS de l'Estrie-CHUS

    Sherbrooke, Quebec, Canada · Recruiting

  • Hospital Sant Joan de Déu

    Esplugues de Llobregat, Barcelona, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.